Education
About Us
Working with TipRanks
Follow Us
Atai Life Sciences N.V. (ATAI)
:ATAI
ATAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.03 - $4.40
Previous CloseN/A
Volume1.44M
Average Volume (3M)7.66M
Market Cap
$841.15M
Enterprise Value$160.71M
Total Cash (Recent Filing)$98.20M
Total Debt (Recent Filing)$26.67M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 18, 2025EPS Estimate
-0.12Last Dividend Ex-Date
Aug 27, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding200,752,780
10 Day Avg. Volume7,926,945
30 Day Avg. Volume7,655,477
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.19
Enterprise Value/Revenue86.27
Enterprise Value/Gross Profit98.12
Enterprise Value/Ebitda-1.11
Forecast
1Y Price Target
$11.14Price Target Upside168.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Bulls Say, Bears Say
Bulls Say
Investor EnthusiasmThe strength of later-stage data from atai and other players, along with support from the FDA, has led to renewed enthusiasm from investors.
Market ValuationWith a more streamlined psychedelic-focused pipeline that includes soon-to-be-wholly-owned BPL-003, which recently had very promising Phase 2b results for treatment-resistant depression, ATAI remains significantly undervalued.
Pipeline PotentialATAI's focus on its psychedelics pipeline, including BPL-003, has shown robust efficacy, a favorable safety profile, and scalability, indicating strong potential for success.
Bears Say
Clinical Development RiskRisks include clinical development risk tied to BPL-003, competitor risk in relevant therapeutic areas, government regulatory risk, capital market and dilution risk, commercialization risk, reimbursement risk, pricing risk, business development risk, and clinical trial risk owing to the war in Eastern Europe.
Clinical Trial OutcomeInidascamine did not meet its primary endpoint in the Phase 2b trial for CIAS, leading to its removal from the valuation model.
Development ChallengesRecognify, which ATAI had a strategic investment in, announced that inidascamine (formerly RL-007), a non-psychedelic, did not meet its primary endpoint in a Phase 2b trial for cognitive impairment associated with schizophrenia.
ATAI Life Sciences News
ATAI FAQ
What was Atai Life Sciences N.V.’s price range in the past 12 months?
Atai Life Sciences N.V. lowest stock price was $1.03 and its highest was $4.40 in the past 12 months.
What is Atai Life Sciences N.V.’s market cap?
Atai Life Sciences N.V.’s market cap is $841.15M.
When is Atai Life Sciences N.V.’s upcoming earnings report date?
Atai Life Sciences N.V.’s upcoming earnings report date is Aug 18, 2025 which is in 9 days.
How were Atai Life Sciences N.V.’s earnings last quarter?
Atai Life Sciences N.V. released its earnings results on May 14, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.171 by $0.021.
Is Atai Life Sciences N.V. overvalued?
According to Wall Street analysts Atai Life Sciences N.V.’s price is currently Undervalued.
Does Atai Life Sciences N.V. pay dividends?
Atai Life Sciences N.V. pays a Notavailable dividend of $6 which represents an annual dividend yield of N/A. See more information on Atai Life Sciences N.V. dividends here
What is Atai Life Sciences N.V.’s EPS estimate?
Atai Life Sciences N.V.’s EPS estimate is -0.12.
How many shares outstanding does Atai Life Sciences N.V. have?
Atai Life Sciences N.V. has 200,752,780 shares outstanding.
What happened to Atai Life Sciences N.V.’s price movement after its last earnings report?
Atai Life Sciences N.V. reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.171. Following the earnings report the stock price went up 1.418%.
Which hedge fund is a major shareholder of Atai Life Sciences N.V.?
Currently, no hedge funds are holding shares in ATAI
ATAI Life Sciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.14 (168.43% Upside)
$11.14 (168.43% Upside)
Blogger Sentiment
Bullish
ATAI Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 672.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.8%
Last 30 Days ▲ 44.0%
Last 30 Days ▲ 44.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
219.23%
12-Months-Change
Fundamentals
Return on Equity
-62.43%
Trailing 12-Months
Asset Growth
-27.25%
Trailing 12-Months
Company Description
Atai Life Sciences N.V.
ATAI Life Sciences is a biopharmaceutical company focused on developing innovative treatments for mental health disorders. It operates primarily in the biotechnology and pharmaceuticals sectors, with a core emphasis on psychedelic and non-psychedelic compounds. The company collaborates with various organizations to accelerate the development of its diverse pipeline of therapeutic candidates, aiming to address unmet medical needs in mental health care.
ATAI Stock 12 Month Forecast
Average Price Target
$11.14
▲(168.43% Upside)
Technical Analysis
Taysha Gene Therapies
―
Olema Pharmaceuticals
―
Monte Rosa Therapeutics
―
Septerna, Inc.
―
Ownership Overview
33.08% Insiders
0.51% Mutual Funds
0.05% Other Institutional Investors
65.43% Public Companies and Individual Investors